BGLC
BioNexus Gene Lab Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · MY
$1.23
+1.48%Oct 7, 2026, 13:02 UTC
BioNexus Gene Lab Corp signed an agreement with Ruanyun Edai Technology Inc. for an exclusive ten-year Malaysian healthcare licence to the CogniAI platform, with two five-year renewal options, in exchange for 410,000 BioNexus shares valued at US$3.5 million and a 10% royalty on defined technology receipts.
Oct 5, 2026, 13:00 UTC
RYET entered an exclusive license agreement with BioNexus Gene Lab to bring Cogni AI into Malaysian healthcare, granting RYET a 10% royalty on qualifying technology receipts and 560,000 BGLC shares in a reciprocal share exchange.
Jul 28, 2026, 13:00 UTC
BioNexus Gene Lab Corp. announced progress toward commercializing the VitaGuard MRD platform in Southeast Asia after a working visit to Tongshu Gene facilities in China.
Source: